CABA Stock Overview
A clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Cabaletta Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$5.06 |
| 52 Week High | US$26.35 |
| 52 Week Low | US$3.47 |
| Beta | 2.4 |
| 11 Month Change | -24.59% |
| 3 Month Change | -54.70% |
| 1 Year Change | -63.41% |
| 33 Year Change | -53.49% |
| 5 Year Change | n/a |
| Change since IPO | -49.40% |
Recent News & Updates
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Sep 04
Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Jun 28Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22Recent updates
We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Sep 04Cabaletta Bio: Next Data Readout Needs To Be Mic Drop Moment
Jun 28Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
May 22Cabaletta Bio: Two Differentiated CAR-T Platforms To Carry It Forward
Jan 31Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Dec 28Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Sep 12Here's Why We're Not Too Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Situation
Jun 04Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Feb 11We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Oct 20We Think Cabaletta Bio (NASDAQ:CABA) Needs To Drive Business Growth Carefully
Jul 07Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Mar 24We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 09We're Not Very Worried About Cabaletta Bio's (NASDAQ:CABA) Cash Burn Rate
Aug 05Cabaletta Bio EPS beats by $0.08
May 03Cabaletta Bio (NASDAQ:CABA) Is In A Good Position To Deliver On Growth Plans
Apr 12What Percentage Of Cabaletta Bio, Inc. (NASDAQ:CABA) Shares Do Insiders Own?
Feb 19
Chardan Capital initiates Cabaletta Bio with Buy rating
Jan 08We're Hopeful That Cabaletta Bio (NASDAQ:CABA) Will Use Its Cash Wisely
Dec 28Dosing underway in Cabaletta Bio's DSG3-CAART study in a rare skin blistering disorder
Dec 09Cabaletta Bio +5% on Q3 results, pipeline update
Nov 10Shareholder Returns
| CABA | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -12.2% | -2.1% | -1.9% |
| 1Y | -63.4% | 13.4% | 20.9% |
Return vs Industry: CABA underperformed the US Biotechs industry which returned 14% over the past year.
Return vs Market: CABA underperformed the US Market which returned 22.7% over the past year.
Price Volatility
| CABA volatility | |
|---|---|
| CABA Average Weekly Movement | 16.3% |
| Biotechs Industry Average Movement | 10.5% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 15.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: CABA's share price has been volatile over the past 3 months.
Volatility Over Time: CABA's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2017 | 137 | Steven Nichtberger | www.cabalettabio.com |
Cabaletta Bio, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases. The company’s lead product candidate is CABA-201, a fully human anti-CD19 binder for the treatment of Phase 1/2 clinical trials in dermatomyositis, anti-synthetase syndrome, immune-mediated necrotizing myopathy, lupus nephritis, non-renal systemic lupus erythematosus, systemic sclerosis, and generalized myasthenia gravis. It also develops DSG3-CAART, which is in Phase I/II clinical trial for the treatment of mucosal pemphigus vulgaris; and MuSK-CAART, an investigational cell therapy that is in Phase I/II clinical trial for treating patients with anti- muscle-specific kinase antibody positive myasthenia gravis.
Cabaletta Bio, Inc. Fundamentals Summary
| CABA fundamental statistics | |
|---|---|
| Market cap | US$275.02m |
| Earnings (TTM) | -US$89.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.7x
P/E RatioIs CABA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CABA income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$89.98m |
| Earnings | -US$89.98m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.84 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did CABA perform over the long term?
See historical performance and comparison